Stay updated on Risankizumab vs Secukinumab in Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    9 days ago
    Change Detected
    Summary
    The clinical trial record for a completed Phase 3 comparison of risankizumab and secukinumab for moderate-to-severe plaque psoriasis is displayed instead of an access-denied error.
    Difference
    78%
    Check dated 2026-11-07T11:07:49.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-31T09:57:03.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH website updates and says the agency is transitioning its terminology from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-24T09:37:01.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The error page’s footer revision label changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T12:22:47.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1 while the page continued to show a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T12:31:39.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, replacing the study record content with an access-denied message. This indicates that the study details are currently blocked from access.
    Difference
    18%
    Check dated 2026-09-19T18:42:12.000Z thumbnail image

Stay in the know with updates to Risankizumab vs Secukinumab in Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Risankizumab vs Secukinumab in Psoriasis Clinical Trial page.